Patents Assigned to YASHIRO CO., LTD.
  • Publication number: 20260207537
    Abstract: A pharmaceutical composition for preventing and treating an aortic aneurysm including a medium chain fatty acid as a main component has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, continuous intake of the composition can not only inhibit the progression of the aortic aneurysm but also mediate the regression of the aortic aneurysm, thereby producing the effect of improving vital prognosis.
    Type: Application
    Filed: March 16, 2026
    Publication date: July 23, 2026
    Applicants: KINKI UNIVERSITY, YASHIRO CO., LTD., OSAKA UNIVERSITY
    Inventors: Nobuhiro ZAIMA, Hirona KUGO, Motohiro KITANO, Yoshinori HIROTA, Ken-ichi HIRANO
  • Publication number: 20260137641
    Abstract: A pharmaceutical composition for preventing an aortic aneurysm is provided including a medium chain fatty acid as a main component, which has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, the composition through continuous intake can exhibit effects including inhibition of the progression of the aortic aneurysm and improvement in the vital prognosis.
    Type: Application
    Filed: January 15, 2026
    Publication date: May 21, 2026
    Applicants: KINKI UNIVERSITY, YASHIRO CO., LTD., OSAKA UNIVERSITY
    Inventors: Nobuhiro ZAIMA, Hirona KUGO, Motohiro KITANO, Yoshinori HIROTA, Ken-ichi HIRANO
  • Publication number: 20240065992
    Abstract: An aortic aneurysm has few noticeable symptoms and is at high risk of rupture without a sign of abnormality. Further, if the aortic aneurysm ruptures, it causes a shock state due to massive blood loss and results in a very low survival rate. Thus, when the aortic aneurysm is found by physical examination or the like, surgery with a stent graft or the like needs to be performed according to the state of its progression. A pharmaceutical composition for preventing and treating an aortic aneurysm including a medium chain fatty acid as a main component has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, continuous intake of the composition can not only inhibit the progression of the aortic aneurysm but also mediate the regression of the aortic aneurysm, thereby producing the effect of improving vital prognosis.
    Type: Application
    Filed: December 10, 2021
    Publication date: February 29, 2024
    Applicants: KINKI UNIVERSITY, YASHIRO CO., LTD., OSAKA UNIVERSITY
    Inventors: Nobuhiro ZAIMA, Hirona KUGO, Motohiro KITANO, Yoshinori HIROTA, Ken-ichi HIRANO
  • Publication number: 20220323385
    Abstract: An aortic aneurysm has few noticeable symptoms and is at high risk for rupture without a sign of abnormality. Further, if it ruptures, it causes a shock state due to massive blood loss and results in a very low survival rate. Thus, when the aortic aneurysm is found by physical examination or the like, a surgery with a stent graft or the like needs to be performed according to the state of its progression. A pharmaceutical composition for preventing an aortic aneurysm including a medium chain fatty acid as a main component has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, the composition through continuous intake can exhibit effects including inhibition of the progression of the aortic aneurysm and improvement in the vital prognosis.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 13, 2022
    Applicants: KINKI UNIVERSITY, YASHIRO CO., LTD., OSAKA UNIVERSITY
    Inventors: Nobuhiro ZAIMA, Hirona KUGO, Motohiro KITANO, Yoshinori HIROTA, Ken-ichi HIRANO